The addition of rituximab to fludarabine and cyclophosphamide improves progression-free survival in patients with previously treated chronic lymphocytic leukemia.

Authors

Amit Mahipal, Thomas Jefferson UniversityFollow
Mark Weiss, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

11-1-2010

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Current Oncology Reports. Volume 12, Issue 6, November 2010, Pages 352-354. The published version is available at DOI: 10.1007/s11912-010-0122-3. Copyright © Springer Inc.

Abstract

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the United States. There has been considerable progress in understanding the biology and treatment of CLL in last 20 years. The introduction of purine analogs (pentostatin, fludarabine, and cladribine) dramatically increased the response rates compared to alkylating agents. Combination chemoimmunotherapy has further improved the overall frequency of response to over 80% in treatment-naïve and over 60% in relapsed/ refractory disease, respectively.

Recommended Citation

Mahipal, Amit and Weiss, Mark, "The addition of rituximab to fludarabine and cyclophosphamide improves progression-free survival in patients with previously treated chronic lymphocytic leukemia." (2010). Department of Medical Oncology Faculty Papers. Paper 2.
https://jdc.jefferson.edu/medoncfp/2

PubMed ID

20809225